Full Disclosure

摘要

New therapies can pass through the regulatory pipeline to the public at large only after researchers vet them in clinical trials. The pioneering patients who enter these studies must balance benefit against risk.rn"People who participate in clinical trials are a rare breed," writes Suzanne Pattee, a 46-year-old cystic fibrosis patient, in the journal Human Gene Therapy.